BioHarvest Sciences

BHST · CANADIAN

$1.72+$0.04 (+2.38%)TodayMarket closed · Oct 23, 6:10 PM ET

Prev close $1.68

BHST analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 4 analysts

Average $9.30 (+440.6% upside)

Low: $8.50
Now: $1.72
High: $10.31

Upgrades and downgrades

The latest rating actions, newest first

BHST analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Maxim Group	Aug 12, 2026	Maintains	Buy	$12.00 → $5.00	26%
Roth Capital	Aug 12, 2026	Maintains	Buy	$10.00 → $8.00	45%
Roth Capital	Feb 19, 2026	Initiates	Buy	$10.00	45%

The case for and against

Updated May 30, 2025

Bull case

BioHarvest Sciences Inc demonstrated significant financial growth, achieving record revenues of $6.5 million in the third quarter of 2024, which represents a substantial year-over-year increase of 102%. The company’s robust performance is largely attributed to its flagship nutraceutical product VINIA, highlighting the strong market demand for its innovative health and wellness offerings. Furthermore, favorable market trends in both the pharmaceutical and cosmetics contract development and manufacturing organization (CDMO) sectors, which are projected to experience considerable growth in the coming years, position BioHarvest’s proprietary botanical synthesis technology favorably within these expanding markets.

Bear case

BioHarvest Sciences Inc. faces significant operational risks stemming from potential difficulties in retaining or replacing key management personnel, which could compromise the company’s efficiency and growth potential. Additionally, the company's reliance on consumer acceptance of new products and its ability to secure contractual agreements with Contract Development and Manufacturing Organizations (CDMOs) raises concerns about revenue generation amidst competitive pressures. Furthermore, challenges in maintaining its intellectual property protections and quality management processes could exacerbate financial vulnerabilities, contributing to a pessimistic outlook regarding its market position and overall financial performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.